Bayer Reports Results of Finerenone in P- III FIGARO-DKD CV Outcomes Study for Chronic Kidney Disease and Type 2 Diabetes

 Bayer Reports Results of Finerenone in P- III FIGARO-DKD CV Outcomes Study for Chronic Kidney Disease and Type 2 Diabetes

Shots:

  • The P-III FIGARO-DKD study involves assessing the efficacy and safety of finerenone (10/20mg, PO, qd) + SoC vs PBO + SoC in ~7400 patients with CKD and T2D at 1,000+ sites across 47 countries globally
  • The study resulted in meeting its 1EPs i.e reduction in the composite risk of time to the first occurrence of CV death and non-fatal CV events or outcomes in patients with CKD and T2D
  • The FDA currently reviews the NDA for Priority Review based on the P-III FIDELIO-DKD study while the data from the FIGARO-DKD study will be presented at an upcoming scientific meeting. Finerenone is an investigational non-steroidal, selective mineralocorticoid receptor antagonist

Click here to­ read full press release/ article | Ref: BUSINESS WIRE | Image: Bayer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post